Skip to content
Biodatica
Start free

MARKER THERAPEUTICS, INC.

HOUSTON, TX

Oncologycell therapyPhase IListed · MRKR

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Sign in to watch

What changed

Phase I trial registered: A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma

5d agoTrial registeredJul 13, 2026Source filing (opens the source filing in a new tab)

Momentum

66no change

Momentum 66 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Sep 30, 2026

    Metastatic Pancreatic Adenocarcinoma · NOT_YET_RECRUITING · sponsor: M.D. Anderson Cancer Center · A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma

    ClinicalTrials.gov · NCT07700212 (opens the source filing in a new tab)

  2. Grant

    R44 · $674k · non-dilutive

    Sep 1, 2024

    MARKER THERAPEUTICS, INC. · PI VERA, JUAN FERNANDO · NCI · award ends Aug 31, 2027 · A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX

    NIH RePORTER · NIH RePORTER 11180449 (opens the source filing in a new tab)

  3. Grant

    R44 · $665k · non-dilutive

    Aug 10, 2023

    MARKER THERAPEUTICS, INC. · PI VERA, JUAN FERNANDO · NCI · award ends Jul 31, 2026 · Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant

    NIH RePORTER · NIH RePORTER 11181329 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources